STERIS plc (NYSE:STE) Forecasted to Earn FY2025 Earnings of $8.87 Per Share

STERIS plc (NYSE:STE) – Investment analysts at Zacks Research increased their FY2025 earnings estimates for shares of STERIS in a report released on Wednesday, September 25th. Zacks Research analyst R. Department now expects that the medical equipment provider will earn $8.87 per share for the year, up from their prior forecast of $8.85. The consensus estimate for STERIS’s current full-year earnings is $9.05 per share. Zacks Research also issued estimates for STERIS’s Q4 2025 earnings at $2.52 EPS, Q4 2026 earnings at $2.59 EPS, FY2026 earnings at $9.47 EPS and FY2027 earnings at $10.01 EPS.

A number of other research analysts also recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of STERIS in a report on Thursday, August 8th. Stephens reissued an “overweight” rating and set a $260.00 target price on shares of STERIS in a research report on Wednesday, August 7th. StockNews.com raised shares of STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. KeyCorp boosted their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. Finally, JMP Securities reissued a “market outperform” rating and set a $265.00 target price on shares of STERIS in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $246.00.

STERIS Stock Up 1.5 %

STERIS stock opened at $242.54 on Monday. The company has a market capitalization of $23.98 billion, a P/E ratio of 62.87 and a beta of 0.83. The firm’s fifty day simple moving average is $237.51 and its 200-day simple moving average is $225.65. The company has a current ratio of 2.33, a quick ratio of 1.49 and a debt-to-equity ratio of 0.35. STERIS has a 1-year low of $195.47 and a 1-year high of $248.24.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The business had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. STERIS’s revenue for the quarter was down .4% on a year-over-year basis. During the same quarter last year, the firm earned $2.00 EPS.

Institutional Trading of STERIS

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in STERIS by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 11,864,606 shares of the medical equipment provider’s stock valued at $2,608,434,000 after acquiring an additional 53,526 shares during the period. Massachusetts Financial Services Co. MA increased its stake in STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after acquiring an additional 778,613 shares during the period. Price T Rowe Associates Inc. MD increased its stake in STERIS by 7.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after acquiring an additional 120,616 shares during the period. Sustainable Growth Advisers LP increased its stake in STERIS by 23.5% in the first quarter. Sustainable Growth Advisers LP now owns 1,485,578 shares of the medical equipment provider’s stock valued at $333,988,000 after acquiring an additional 282,387 shares during the period. Finally, Impax Asset Management Group plc increased its stake in STERIS by 29.7% in the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock valued at $251,663,000 after acquiring an additional 263,383 shares during the period. Institutional investors own 94.69% of the company’s stock.

Insider Transactions at STERIS

In other news, Director Christopher S. Holland sold 473 shares of the business’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now owns 582 shares in the company, valued at approximately $139,493.76. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the sale, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher S. Holland sold 473 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

STERIS Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, September 5th were issued a dividend of $0.57 per share. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, September 5th. This represents a $2.28 annualized dividend and a dividend yield of 0.94%. STERIS’s payout ratio is presently 59.69%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.